Lee Landenberger
January 31, 2024
Halia Therapeutics Inc. has, its CEO confidently asserts, taken an atypical road to building its infrastructure and financing. The Lehi, Utah-based company just completed a $30 million series C financing to further develop its lead asset, a selective and orally bioavailable first-in-class NLRP3/NEK7 inflammasome inhibitor.
See the full article at the link below.
To learn more about the inflammasome inhibitors we are developing visit our pipeline page.